Clinical Trial

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-01 -> 2026-07-31 2026-06-19
minor Completion pushed: 2026-07-01 -> 2026-07-31 2026-06-19
Trial Details
NCT Number NCT04255849
Lead Sponsor Weill Medical College of Cornell University
Collaborators: H. Lee Moffitt Cancer Center and Research Institute, University of Sao Paulo, University of Puerto Rico, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, University of California, San Diego, Instituto Nacional de Salud Publica, Mexico
Conditions HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
Enrollment 700 participants
Start Date 2021-02-23
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18